Evaluation of intrinsic and extrinsic risk factors for dog visceral hemangiosarcoma: A retrospective case-control study register-based in Lazio region, Italy

Carnio, Azzurra; Eleni, Claudia; Cocumelli, Cristiano; Pino, Leticia Elisa Bartolomé Del; Simeoni, Sara; Spallucci, Valentina; Scaramozzino, Paola

doi:10.1016/j.prevetmed.2020.105074

Cited by 18 publications

(18 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The extent to which these factors contribute to malignant or benign tumour susceptibility has rarely been addressed. Our results showing no difference in lifetime prevalence of malignant or benign tumours between purebred and mixed breed dogs are consistent with one prior study that relied on cancer prevalence 23 and the majority of prior studies that relied on incidence 3,9,24,25 (Two studies measuring cancer incidence reported higher rates in purebred compared to mixed breed dogs 4,7 ).…”

Section: Characteristics Associated With Lifetime Cancer Prevalencesupporting

confidence: 90%

“…The extent to which Peto's Paradox holds among dogs, however, has only infrequently been assessed. Risks of appendicular osteosarcoma and hemangiosarcoma have been reported to be increased in several large dog breeds and reduced in small dog breeds 24,27 . Further, whether cancer risk differs according to dog size class may vary according to cancer site 9 …”

Section: Discussionmentioning

confidence: 99%

“…Risks of appendicular osteosarcoma and hemangiosarcoma have been reported to be increased in several large dog breeds and reduced in small dog breeds. 24,27 Further, whether cancer risk differs according to dog size class may vary according to cancer site. 9 We found that the age-adjusted lifetime prevalence of malignant and benign tumours increased with increasing size class.…”

Section: Dog Size Classmentioning

confidence: 99%

See 2 more Smart Citations

Lifetime prevalence of malignant and benign tumours in companion dogs: Cross‐sectional analysis of Dog Aging Project baseline survey

Schwartz,

Urfer,

White

et al. 2022

Vet Comparative Oncology

View full text Add to dashboard Cite

Although cancer is widely regarded as a major contributor to canine morbidity and mortality, its frequency in companion dogs has only infrequently been characterised. We analysed cross‐sectional data from the baseline survey of owners of 27 541 living companion dogs enrolled in the Dog Aging Project as of 31 December 2020 to estimate the lifetime prevalence of malignant and benign tumours and several potentially‐associated characteristics. Survey questions elicited information on history of ‘cancer or tumors’ including organ site and histologic type. Owners reported 819 malignant tumours (56% sited in the skin, muscle or other soft tissue) and 404 benign tumours (69% sited in the skin, muscle or other soft tissue). The lifetime prevalence of malignant tumours (29.7/1000 dogs) was approximately double the lifetime prevalence of benign tumours (14.7/1000 dogs). Lifetime prevalence of both malignant and benign tumours increased with dog age at survey completion. There were no statistically discernable differences in age‐adjusted lifetime prevalence of malignant (prevalence ratio (PR) = 0.93 [95% confidence interval (CI) 0.82, 1.07] or benign tumours (PR = 1.10, 95% CI 0.91, 1.34) in mixed vs. purebred dogs. The lifetime prevalence of malignant tumours increased with increasing dog size class; compared to toy and small dogs, the age‐adjusted PRs (95% CIs) for medium, standard, large, and giant dogs were 1.65 (1.28, 2.11), 2.92 (2.35, 3.64), 3.67 (2.92, 4.62) and 2.99 (1.23, 4.02), respectively. Similar though less pronounced patterns in relation to dog size class were observed for benign tumours. Ongoing prospective data collection will permit future studies on risk factors for canine tumour incidence.

show abstract

Section: Characteristics Associated With Lifetime Cancer Prevalencesupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Dog Size Classmentioning

confidence: 99%

See 1 more Smart Citation

Lifetime prevalence of malignant and benign tumours in companion dogs: Cross‐sectional analysis of Dog Aging Project baseline survey

Schwartz,

Urfer,

White

et al. 2022

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…In our study, we found high expression in the cavernous and differentiated histological subtypes. Claudin-5 could be used as a marker with greater sensitivity and could also be of diagnostic value in the differential diagnosis of canine HSAs from other sarcomas with hemorrhage or increased vascularization [16,17,[32][33][34]. Claudin-5 might also represent an interesting prognostic marker for canine HSA metastasis.…”

Section: Discussionmentioning

confidence: 99%

Investigation of Prognostic Value of Claudin-5, PSMA, and Ki67 Expression in Canine Splenic Hemangiosarcoma

Rozolen

Teodoro

Sobral³

et al. 2021

Animals

View full text Add to dashboard Cite

Splenic hemangiosarcoma (HSA) is a malignant tumor of endothelial cells that affects middle-aged and elderly dogs and is characterized by the formation of new blood vessels, commonly associated with necrotic and hemorrhagic areas. Despite its importance in veterinary medicine, few studies have identified markers with prognostic value for canine HSA. Thus, this study aimed to associate the clinicopathological findings (prostate-specific membrane antigen [PSMA], Claudin-5, and Ki67 gene and protein expression) with overall survival in HSA-affected patients. Fifty-three formalin-fixed and paraffin-embedded canine splenic HSA samples, previously diagnosed by histopathological examination, were used in this study. Claudin-5, PSMA, and Ki67 protein expression levels were evaluated by immunohistochemistry, and gene expression was evaluated by quantitative polymerase chain reaction. Claudin-5 protein overexpression was observed in patients with metastasis (p = 0.0078) and with stage III tumors compared to those with stage I and II tumors (p = 0.0451). In patients treated with surgery alone, low PSMA gene and protein expression (p = 0.05 and p = 0.0355, respectively) were associated with longer survival time. Longer survival time was observed in patients with a low Ki67 index (p = 0.0488). Our results indicate that Claudin-5 protein expression is associated with metastatic status, and PSMA gene and protein expression, and Ki67 index are associated with survival time.

show abstract

“…CDKN2A is a known tumor-suppressor gene and frequent deletions and copy number losses have been documented in both radiation-induced AS and canine HSA. 55 Because these three breeds have different average lifespans, it is difficult to ascertain whether German Shepherds (mean lifespan of 10.3 years) age more rapidly compared to Golden retrievers (mean lifespan 12 years) and Labrador retrievers (12.6 years) [56][57][58] , or if instead they age at the same rate, but their strong predisposition to HSA [56][57][58][59] and tendency towards shorter OST depress the breed's overall average survival. As golden retrievers and Labrador retrievers also have a high HSA risk, differences in genetic background and aging may be playing a role.…”

Section: Germline Backgroundmentioning

confidence: 99%

Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma

Estabrooks

Gurinovich

Pietruska³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Canine hemangiosarcoma (HSA) is an aggressive cancer of endothelial cells associated with short survival times. Understanding the genomic landscape of HSA is critical to developing more effective therapeutic strategies. Objectives: To determine the relationships between genomic and clinical features including treatment and outcome in canine splenic HSA. Animals: 109 dogs with primary splenic HSA treated by splenectomy that had tumor sequencing via the FidoCure® Precision Medicine Platform targeted sequencing panel. Methods: Patient signalment, weight, metastasis at diagnosis, treatment, and survival time were retrospectively evaluated. The incidence of genomic alterations in individual genes and their relationship to patient variables and outcome were assessed. Results: Somatic mutations in TP53 (n = 45), NRAS (n = 20), and PIK3CA (n = 19) were most common. Survival was associated with metastases at diagnosis, germline variants in SETD2 and NOTCH1, and nominally with breed. Age at diagnosis was associated with NRAS mutations and breed. TP53 and PIK3CA mutations were found in larger dogs, germline SETD2 variants in smaller dogs. Doxorubicin (DOX) treatment did not significantly improve survival time, while targeted therapies had a significant early survival benefit. Conclusions and clinical importance: DOX treatment may provide limited clinical benefit for dogs with splenic HSA, while targeted therapy may provide early survival benefit. Genetic signatures associated with splenic HSA may be useful in guiding targeted therapy to improve outcomes. Germline variants, age, size, and breed may be useful prognostic factors and provide insight into the genomic landscape of the tumor.

show abstract

Evaluation of intrinsic and extrinsic risk factors for dog visceral hemangiosarcoma: A retrospective case-control study register-based in Lazio region, Italy

Cited by 18 publications

References 22 publications

Lifetime prevalence of malignant and benign tumours in companion dogs: Cross‐sectional analysis of Dog Aging Project baseline survey

Lifetime prevalence of malignant and benign tumours in companion dogs: Cross‐sectional analysis of Dog Aging Project baseline survey

Investigation of Prognostic Value of Claudin-5, PSMA, and Ki67 Expression in Canine Splenic Hemangiosarcoma

Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma

Contact Info

Product

Resources

About